



Global Health
EDCTP3

EU policy context



EU Global Health Strategy – Better health for all in a changing world

- The Commission adopted the [strategy](#) on 30 November 2022 as part of [EU Global Gateway](#).
- In January 2024, the Council [welcomed the EU Global Health Strategy](#) and its three priorities:
 - Deliver better health and well-being across the life course
 - Strengthen health systems and advance universal health coverage, including research
 - Prevent and combat health threats, including pandemics, through One Health
- Expand bilateral, regional, and global partnerships through Team Europe approach
- [Global Health EDCTP3 JU](#) mentioned as key initiative, also building on the AU-EU Innovation Agenda



European Commission | English | Search

Home > Press corner > EU Global Health Strategy

Available languages: English

Press release | 30 November 2022 | Brussels

EU Global Health Strategy to improve global health security and deliver better health for all

Page contents

Top

Quote(s)

Twitter feed

Print friendly pdf

Press contact

Today, the Commission adopted a new EU Global Health Strategy to improve global health security and deliver better health for all in a changing world. With the Strategy, the EU deepens its leadership and reasserts its responsibility for tackling key global challenges and health inequalities head-on: the unfinished agenda in global health and combatting health threats in the age of pandemics.

The Strategy positions global health as an essential pillar of EU external policy, a critical sector geopolitically and central to EU strategic autonomy. It promotes sustainable, meaningful partnerships of equals drawing on the [Global Gateway](#). As the [external dimension of the European Health Union](#), the strategy is designed to guide EU action for ensuring better preparedness and response to health threats in a

Strengthening Europe's Clinical Research Ecosystem

- **Strategy for the European Life Sciences:** Life Science sector key for competitiveness and strategic autonomy
- **Draghi Report (2024):** Recommends streamlining the set-up and management of multi-country trials in the EU, and stresses its effect to solidify expertise and capacity within the EU in conducting clinical R&D
- **Letta Report (2024):** Underlines how the Single Market can be a useful tool to streamline the clinical trial process, thereby making the EU more attractive for clinical research investments
- **Start-up & Scale-up agenda**
 - Support biotech & health-tech start-ups from early research → clinical application
 - Enable scale-up: expand trial networks, infrastructures & partnerships
 - Encourage fast-track regulatory pathways and funding access



Clinical Research Investment Plan



- The Strategy for the European Life Sciences announces a **Clinical Research Investment Plan** to:
 - Facilitate funding for multi-country clinical trials, in compliance with competition rules
 - Further develop and streamline European research infrastructures in the field of clinical research
- Vision: Advancing towards a **single market for clinical research** and **reducing fragmentation**
- Supporting both **non-commercial** and **commercial** sponsors
- **Non-regulatory initiative** complementing regulatory measures
 - Revision of the Clinical Trials Regulation in the European Biotech Act (16 Dec 2025)

Horizon Europe Support for Clinical Trials

- Horizon Europe is one of the main sources of funding for clinical research in Europe and globally
 - Research Partnerships with Member States and Associated Countries
 - ERA4HEALTH: Supports academic, multi-country clinical trials on non-communicable diseases
 - BE READY: Focuses on clinical trials for infectious diseases and pandemic preparedness
 - ERDERA: Dedicated to support clinical trials for rare diseases
 - Joint Undertakings
 - Global Health EDCTP3: Facilitates collaboration between the EU and African countries to strengthen research capacity, including clinical trials on poverty-related and neglected infectious diseases
 - IHI: Encourages collaboration across public and private sectors, funding projects that involve clinical trials, especially those focused on pioneering health solutions and treatments
 - EU Cancer Mission
 - Providing funding for projects conducting clinical trials in prevention, diagnostics, treatment and quality of life.
 - Regular calls for projects in the Health cluster
 - Research infrastructures
 - European Clinical Research Infrastructure Network (ECRIN), Biobanking and BioMolecular Resources Research Infrastructure (BBMRI), European Infrastructure for Translational Medicine (EATRIS)

AU-EU Health Partnership between Team Europe and Africa Union

Hubs

- Sustainable health security using a "One Health" approach
- Support to Public Health Institutes in Sub-Saharan Africa
- Digital health for health systems strengthening and universal health coverage
- Manufacturing and access to vaccines, medicines and health technologies (MAV+)
- Sexual and reproductive health and rights

AU-EU Health Partnership between Team Europe and Africa Union

- EDCTP3 WP 2026, 4.1.2.3 General conditions related to this work programme:

“Where relevant, it will be important for proposals to show in their dissemination and exploitation plans consideration and support to the existing and emerging partnerships between the EU/Team Europe (EU institutions, Member States and EU Financing Institutions) and the African Union (AU) and their key agencies, notably the AU-EU Health Partnership hubs Access to Vaccines, medicines and health technologies (MAV+), Sustainable Health Security, Public Health Capacity, Digital Health)”.

- Explain the potential impact of the proposed project and the quality of the implementation, including the collaboration with industrial or commercial partners or with relevant networks for the addressed topics.

Sustainable Health Security using a “One Health” approach

- Initiative launched in 2024, strengthens health systems and capacities for sustainable prevention, preparedness and response to infectious threats and antimicrobial resistance in Africa, using a One Health approach, including laboratories, surveillance systems and workforce development.
- Funded by the European Commission and EU MS including Belgium, Denmark, France, Germany, Spain and Sweden (EUR 430 million in over 70 projects).
- Working with Africa CDC to strengthen capacity for continental One Health coordination and Africa CDC's framework for partnership management and with the AU Member States to support the development and rollout of national strategies for AMR, Food Safety, and Climate Change and Health
- Strengthening capacities of Africa CDC in preparedness, response, and emergency operations; improved surveillance, prevention and control of AMR including enhanced laboratory capacity and foster partnerships between European and African stakeholders.
- **Relevant for EDCTP3 call applicants:** consider OneHealth approach, partnerships, synergies, future research results exploitation.
- https://capacity4dev.europa.eu/resources/team-europe-tracker/partner-countries/sub-saharan-africa/public-health-capacity-africa_en



Support to Public Health Institutes in Sub-Saharan Africa

- Initiative launched in 2024 strengthens the institutional capacity of National Public Health Institutes (NPHIs), promotes regional collaboration and networking among African and European institutes, enhances health workforce training, supports evidence-based policy analysis and advice
- Funded by the European Commission, Belgium, Czechia, Finland, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, together with Africa CDC. (EUR 140 million in over 70 projects)
- The EC funded new support to African Public Health Institutes (EUR 50 million 2024-2027) is to be implemented in 10 AU MS countries alongside a regional programme in collaboration with Africa CDC: build NPHIs core capacities and leverage synergies with the other hubs on pandemic preparedness, digital health, sexual and reproductive health and medical products.
- **Relevant for EDCTP3 call applicants:** consider partnerships, networks, synergies, future research results exploitation
- https://capacity4dev.europa.eu/resources/team-europe-tracker/partner-countries/sub-saharan-africa/sustainable-health-security-africa_en



Digital Health for health systems strengthening and universal health coverage

- Joint AU–EU collaboration launched in 2024 to accelerate health systems strengthening and the achievement of universal health coverage through digital health initiatives.
- Funded by the European Commission and EU MS including Belgium, France, Germany, Portugal, Spain and Sweden to support African partners at continental, regional and national level in using digital solutions to strengthen health systems. Ongoing EU programmes:
 - Collaborating with WHO to roll out the Global Digital Health Certificate Network for the verification of health documents.
 - Strengthen Primary Health Care (PHC) through supporting the implementation of the Africa CDC Digital Transformation Strategy at continental/regional level and in 6 countries (Mauritania, Nigeria, CAR, Burundi, Madagascar and Ethiopia)
 - Partnership with UNICEF to support the rollout of the Traceability and Verification System (TRVST) to manage the risk of falsified vaccines and pharmaceuticals.
- **Relevant for EDCTP3 call applicants:** consider partnerships, networks, cross-cutting synergies, future research results exploitation
- https://capacity4dev.europa.eu/resources/team-europe-tracker/partner-countries/sub-saharan-africa/digital-health-africa_en




Manufacturing and Access to vaccines, medicines and health products (MAV+)

- MAV+ is a large initiative (almost € 2 bn committed since 2021) **supporting local manufacturing and access to health products in Africa**, funded by the European Union, Belgium, France, Germany, Luxembourg, Spain, Sweden, The Netherlands and EIB.
- Financial and non-financial support through over 80 projects to industrial development, access to finances, market shaping and demand, technology transfer, regulation and research capacities.
- Continental and regional projects together with partners in Africa: Africa CDC, AMA, AUDA-NEPAD; in Europe: EMA; and international: WHO, Gavi, Gates, CEPI.
- National programs in South Africa, Senegal, Rwanda, Ghana, Nigeria together with the EU Delegations, development agencies, banks, private sector and other local partners.
- Developed financial instruments that can support private sector to invest in Africa.
- **Relevant for EDCTP3 call applicants:** consider future research results exploitation, advanced validation of health products in clinical trials, partnership with industry and local manufacturers, use of MAV+ financial instruments (HDX).
- https://international-partnerships.ec.europa.eu/policies/team-europe-initiatives/team-europe-initiative-manufacturing-and-access-vaccines-medicines-and-health-technologies-africa_en



Human Development Accelerator (HDX)

- Line of credit from EIB guaranteed by the European Commission and in partnership with Gates Foundation.
- Objective is to support local and European companies operating in partner countries.
- Focus on health with a wide scope, including Nutrition
- Of the 750 M:
 - € 650 M Sub-Saharan Africa
 - € 90 M Asia
 - € 20 M LAC (**already used**)
- EIB can take up to 50% of the total investment
- Investments of minimum € 20 M (€10 M from HDX)
- Recipients: Private companies with a sound business model that allows them to repay the loan
- Investment term < 12 years
- Entry point: miguel.campo-llopis@ec.europa.eu



Human Development Accelerator (HDX)

Instruments



Financial Products offered

Venture Debt

High-risk investments similar to equity (without diluting ownership) - repayable based on milestones / outcomes

Corporate Loans

Long term financing at attractive rates to finance corporate activities or initiatives

Volume / Procurement Guarantees


Guarantee for a **minimum quantity or price** to incentivise expansion in production and reduce costs for manufacturers

Possible areas of Investment



Research and Development (R&D)

Financing R&D activities / late-stage development for key **health & nutrition products for LMICs**



Manufacturing

Financing capex costs for the construction / expansion of **manufacturing facilities in LMICs**



Supply Chains

Providing guarantees to ensure supply of key **health & nutrition products**